Pulse Biosciences

Historical price data

Pulse Biosciences' mission is to revolutionize tissue ablation through its proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology, which uses ultra-short electrical pulses to induce cell death while preserving non-cellular tissue architecture. The company has achieved significant milestones, including promising first-in-human feasibility data for its cardiac catheter in atrial fibrillation, live case demonstrations at major cardiology conferences, and 510(k) submissions for its cardiac clamp and percutaneous electrode. Its strategy is to first secure regulatory clearances in high-impact cardiac and thyroid applications, leveraging the unique safety and speed profile of nsPFA to capture share in multi-billion-dollar ablation markets.

Patented nPulse™ platform delivering Nanosecond Pulsed Field Ablation (nsPFA™) energy, which uses ultra-short electrical pulses to selectively ablate cells via intracellular targeting while sparing the extracellular matrix for non-thermal tissue ablation.

Pulse competes with giants in thermal ablation (J&J, Abbott, Medtronic) and newer microsecond PFA systems (Boston Scientific's Farapulse). Its key differentiator is the nanosecond pulse duration, which is unproven clinically but theorized to offer superior intracellular targeting and tissue preservation compared to existing technologies.